37 results about "Secondary osteoporosis" patented technology

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification.) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and / or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and / or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.

A controlled release pharmaceutical composition comprising a strontium salt. The invention also relates to the use of a strontium salt for treating a male suffering from diseases and conditions affecting metabolism and / or structural integrity of cartilage and / or bone. The invention also relates to the use of a strontium-containing compound for preventing a cartilage and / or bone condition in a subject, and for the treatment and / or prophylaxis of secondary osteoporosis.

An application of nano (0.1-1000 nm) copper powder in preparing the medicines to prevent and treat osteoporosis and bone fracture is disclosed. Its advantages are sure curative effect and low toxic by-effect.

The present invention mainly relates to a traditional Chinese medicine composition for treating osteoporosis and a preparation process thereof. The formula is composed of 25-35 parts of raw material Radix Astragali, 13-17 parts of Codonopsis pilosula, 10-14 parts of Angelica sinensis and 14 parts of Eucommia ulmoides in parts by weight. -16 parts, 14-16 parts of Epimedium, 9-11 parts of Yuanhu, 9-11 parts of Myrrha and 16-20 parts of Spatholobus Spatholobus. The traditional Chinese medicine composition provided by the invention has the effects of invigorating the kidney and strengthening the spleen, nourishing blood and promoting blood circulation, strengthening tendons and bones, dredging collaterals and relieving pain, can effectively treat primary and secondary osteoporosis, and treat spleen and kidney deficiency and blood stasis. It has a significant curative effect on symptoms such as soreness in the back and back, sagging waist, soreness and numbness of the limbs, fatigue, dizziness, and cramps in the legs and feet. The preparation process of the present invention is simple and the production cost is low. In the process, half of Astragalus membranaceus and Codonopsis pilosula are decocted with Epimedium, Yuanhu and Caulis Spatholobus, and half are made into powder with angelica, eucommia and myrrh, so that the prepared medicine has a remarkable effect , suitable for popularization and application.

The invention relates to the field of traditional Chinese medicine, in particular to application of Sanhuang hypoglycemic tablets in preparation of medicine for treating type-2 diabetes osteoporosis. The Sanhuang hypoglycemic tablets are prepared from radix astragali, radix rehmanniae, radix et rhizoma rhei, rhizoma dioscoreae, radix puerariae and radix glycyrrhizae. According to the application of the Sanhuang hypoglycemic tablets in preparation of the medicine for treating type-2 diabetes osteoporosis, on the basis of the remarkable curative effect of the Sanhuang hypoglycemic tablets in clinical treatment of type-2 diabetes, the curative effect of the Sanhuang hypoglycemic tablets on type-2 diabetic complications is further explored, during which it is found that the Sanhuang hypoglycemic tablets can have a remarkable curative effect on secondary osteoporosis caused by type-2 diabetes; and verification is carried out through animal experiments. Compared with current medicine for clinically treating type-2 diabetes osteoporosis, the Sanhuang hypoglycemic tablets have the effects of less medicine taking, few contraindications, small side effects and remarkable curative effect.

The invention relates to a new application of a HuGu capsule (HG) in preventing glucocorticoid-induced osteoporosis (GIO), belonging to the technical field of traditional Chinese medicine application. The invention discusses HG prevention effect towards GIO induced by glucocorticoids (GCs) based on bone histomorphometry. The experimental result proves that the glucocorticoids (GCs) can induce cortical bone loss of a rat in short time, after HG intervention is carried out for 45d, the GCs is prevented from inducing the cortical bone loss of the rat, thereby providing experimental proof for thenew application of the HG in preventing the GIO.

The invention features polypeptides that include an extracellular ActRlla variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRlla variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving bone damage, e.g., primary osteoporosis, secondary osteoporosis, osteopenia, osteopetrosis, fracture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.

The invention belongs to the technical field of medicines, and in particular relates to a traditional Chinese medicine for treating ankylosing spondylitis secondary osteoporosis and a preparation method of the traditional Chinese medicine. The traditional Chinese medicine for treating ankylosing spondylitis secondary osteoporosis is prepared from the following traditional Chinese medicines in parts by weight: 15-25 parts of leonurus, 25-35 parts of Chinese angelica, 25-35 parts of ginseng, 25-35 parts of astragalus membranaceus, 25-35 parts of deer-horn glue, 25-35 parts of turtle shell glue, 25-35 parts of the fruit of Chinese wolfberry, 15-25 parts of radix paeoniae alba, 15-25 parts of pseudo-ginseng, 15-25 parts of lumbricus, 15-25 parts of stiff silkworm, 9-15 parts of prepared frankincense, 9-15 parts of prepared myrrh, 15-25 parts of wadalee-gum-tree, 25-35 parts of the root of bidentate achyranthes, 15-25 parts of rheum officinale, 15-25 parts of kadsura root-bark, 15-25 parts of cassia twig, 15-25 parts of poria cocos, and 15-25 parts of sea horse. The Traditional Chinese medicine disclosed by the invention has the effects of supplying vital essence and marrow, enriching blood, invigorating the circulation of blood, dispersing blood stasis and dredging collaterals and can be used for clinically treating ankylosing spondylitis secondary osteoporosis, and therefore, the ankylosing spondylitis symptom can be improved while bone mineral density is increased.

The invention discloses application of a compound traditional Chinese medicine to prevention and treatment of an osteoporosis disease, belonging to new application of the traditional Chinese medicine. The compound traditional Chinese medicine is prepared from the following Chinese medicinal herbs in percentage by weight: 15-35 percent of glossy privet fruit, 10-25 percent of Japanese thistle herbor root, 5-20 percent of largehead atractylodes rhizome, 5-20 percent of root of red-rooted salvia, 5-15 percent of coptis root, 5-15 percent of pseudo-ginseng root, 5-15 percent of eucommia and 5-15percent of fingered citron. As proved by an experiment, the compound traditional Chinese medicine has remarkable treatment effects on the prevention and treatment of primary osteoporosis, secondary osteoporosis, osteoporosis caused by hyperlipidaemia or an osteoporosis disease caused by glucose metabolism syndrome, definite clinical curative effect and no remarkable side effect according to observation.